GLP1R and stroke disorder: To date, cardiovascular outcome studies show that GLP-1 receptor (GLP-1R) agonists reduce atherosclerotic events including myocardial infarction and stroke, and also prevent progression of chronic kidney disease in type-2 diabetic patients [3–5].